Biomarkers for the diagnosis of thyroid cancer

Journal of Experimental Therapeutics and Oncology

Volumn 8, Issue 4, 2010, Pages 341-362

  Sethi, Kruttibas ^a   Sarkar, Siddik ^a   Das, Subhasis ^a   Mohanty, Biswanarayan ^b   Mandal, Mahitosh ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY   (India)

^b SCB Medical College   (India)

Author keywords

Biomarkers; EGFR; FNAC; GAL 3; HBME 1; Immunohistochemical markers; Thyroid carcinoma

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; EMAXANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GALECTIN 3; HECTOR BATTIFORA MESOTHELIAL ANTIGEN 1; PROTEIN; RADIOACTIVE IODINE; SORAFENIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER SURGERY; DISEASE SEVERITY; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA;

GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650095658     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Bojunga J, Zeuzem S. Molecular detection of thyroid cancer: an update. Clin Endocrinol (Oxf) 61: 523-530, 2004.
2. Chen H, Nicol TL, Udelsman R. Follicular lesions of the thyroid. Does frozen section evaluation alter operative management? Ann Surg 222: 101-106, 1995.
3. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 83: 2638-2648, 1998.
4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167, 2006.
5. Utiger RD. The multiplicity of thyroid nodules and carcinomas. N Engl J Med 352: 2376-2378, 2005.
6. Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol 11: 1093-10937, 2004.
7. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 245: 366-378, 2007.
8. Rosai J, Carcangiu ML, De Lellis R. Tumors of the Thyroid Gland. 3 rd series, fascicle 5. In: Rosai J, Sobin LH, eds. Atlas of Tumor Pathology. Washigton: John Wiley & Sons, Ltd.: 207-245, 1992.
9. Sobi LH, Wittekid C. TNM Classification of Malignant Tumors. 6th ed. International Union Against Cancer. New York: Wiley-Liss, 2002.
10. Trovato M. New Research Communication on Thyroid Tumor Markers. In: Sinise GA, ed. Tumor Markers Research Perspectives. New York: Nova Publishers : 191-202, 2007.
11. Schlumberger M.. Papillary and follicular thyroid carcinoma. Ann. Endocrinol(Paris) 68: 120-128, 2007.
12. Ball DW. Medullary thyroid cancer: Monitoring and therapy. Endocrinol Metab Clin North Am 36: 823-837, 2007.
13. Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neo plastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer 77: 750-756, 1996.
14. Wells SA, Jr., Franz C. Medullary carcinoma of the thyroid gland. World J Surg 24: 952-956, 2000.
15. Roman S, Mehta P, Sosa JA. Medullary thyroid cancer: early detection and novel treatments. Curr Opin Oncol 21: 5-10, 2009.
16. Pellegriti G, Giuffrida D, Scollo C, Vigneri R, Regalbuto C, Squatrito S, Belfiore A. Long-term outcome of patients with insular carcinoma of the thyroid: the insular histotype is an independent predictor of poor prognosis. Cancer 95: 2076-2085, 2002.
17. Lin JD, Hsueh C, Chao TC. Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid 19: 1053-1059, 2009.
18. Lentsch EJ.Thyroid, Papillary Carcinoma, Early. http://emedicine. medscape.com/article/849000-overview,2009.
19. Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, Mandal M, Myers JN. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 4: 632-640, 2005.
20. Lin JD, Chao TC, Chen ST, Huang YY, Liou MJ, Hsueh C. Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging. Surg Oncol 16: 107-113, 2007.
21. Pallante P, Visone R, Croce C, Fusco A. Deregulation of microRNA expression in follicular cell-derived human thyroid carcinomas. Endocr Relat Cancer 17: 91-104, 2010.
22. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol 19: 1631-1637, 2006.
23. Abraham D, Gault PM, Hunt J, Bentz J. Calcitonin Estimation in Neck Lymph Node Fine-Needle Aspirate Fluid Prevents Misinterpretation of Cytology in Patients with Metastatic Medullary Thyroid Cancer. Thyroid 19: 1015-1016, 2009.
24. De Micco C, Savchenko V, Giorgi R, Sebag F, Henry JF. Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br J Cancer 98: 818-823, 2008.
25. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18: 48-57, 2005.
26. Eszlinger M, Wiench M, Jarzab B, Krohn K, Beck M, Lauter J, Gubala E, Fujarewicz K, Swierniak A, Paschke R. Meta- and reanalysis of gene expression profiles of hot and cold thyroid nodules and papillary thyroid carcinoma for gene groups. J Clin Endocrinol Metab 91: 1934-1942, 2006.
27. Finn SP, Smyth P, Cahill S, Streck C, O'Regan EM, Flavin R, Sherlock J, Howells D, Henfrey R, Cullen M, Toner M, Timon C, O'Leary JJ, Sheils OM. Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. Virchows Arch 450: 249-260, 2007.
28. Wells SA, Santoro M. Targeting the RET Pathway in Thyroid Cancer. Clinical Cancer Research 15: 7119-7123, 2009.
29. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16: 17-44, 2009.
30. Kato MA, Fahey TJ. Molecular Markers in Thyroid Cancer Diagnostics. Surgical Clinics of North America 89: 1139-+, 2009.
31. Vriens MR, Schreinemakers JMJ, Suh I, Guerrero MA, Clark OH. Diagnostic markers and prognostic factors in thyroid cancer. Future Oncol 5: 1283-1293, 2009.
32. Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 3: 260-269, 2007.
33. Misso C, Calzolari F, Puxeddu E, Lucchini R, Monacelli M, Giammartino C, Sanguinetti A, d'Ajello M, Ragusa M, Avenia N. Persistent hypercalcitoninemia in patients with medullary thyroid cancer. Tumori 95: 484-487, 2009.
34. Machens A, Dralle H. Significance of Marginally Elevated Calcitonin Levels in Micromedullary Thyroid Cancer. Ann Surg Oncol 16: 2960-2960, 2009.
35. Kwaspen FH, Smedts FM, Broos A, Bulten H, Debie WM, Ramaekers FC. Reproducible and highly sensitive detection of the broad spectrum epithelial marker keratin 19 in routine cancer diagnosis. Histopathology 31: 503-516, 1997.
36. Hassanien AS, Nossier MM, Zahran NM, Wahdan MS, Swellam T, Aboul-Magd, DA. The Role of Cytokeratin-19 in Diagnosis of Cancer Bladder. Res J Medicine & Med Sci 4: 128-135, 2009.
37. Rorive S, Eddafali B, Fernandez S, Decaestecker C, Andre S, Kaltner H, Kuwabara I, Liu FT, Gabius HJ, Kiss R, Salmon I. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod Pathol 15: 1294-1301, 2002.
38. Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park do J, Jang HC, Park SH, Cho BY, Park SY. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 22: 621-628, 2007.
39. Laco J, Ryska A, Cap J, Celakovsky P. Expression of galectin-3, cytokeratin 19, neural cell adhesion molecule and E-cadhedrin in certain variants of papillary thyroid carcinoma. Cesk Patol 44: 103-107, 2008.
40. Saleh HA, Feng J, Tabassum F, Al-Zohaili O, Husain M, Giorgadze T. Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. Cytojournal 6: 18-18, 2009.
41. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14: 338-342, 2001.
42. Miettinen M, Karkkainen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours - Preferential reactivity with malignant tumours. Virchows Arch 429: 213-219, 1996.
43. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47: 391-401, 2005.
44. Nga ME, Lim GS, Soh CH, Kumarasinghe MP. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol 36: 550-556, 2008.
45. Almkvist J, Karlsson A. Galectins as inflammatory mediators. Glycoconj J 19: 575-581, 2004.
46. Mathieu A, Saal I, Vuckovic A, Ransy V, Vereerstraten P, Kaltner H, Gabius HJ, Kiss R, Decaestecker C, Salmon I, Remmelink M. Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol 18: 1264-1271, 2005.
47. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357: 1644-1650, 2001.
48. Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y, de la Chapelle A. CITED1 protein expression suggests Papillary Thyroid Carcinoma in high throughput tissue microarray-based study. Thyroid 14: 169-175, 2004.
49. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 98: 15044-15049, 2001.
50. Scarpino S, Stoppacciaro A, Ballerini F, Marchesi M, Prat M, Stella MC, Sozzani S, Allavena P, Mantovani A, Ruco LP. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol 156: 831-837, 2000.
51. Trovato M, Villari D, Bartolone L, Spinella S, Simone A, Violi MA, Trimarchi F, Batolo D, Benvenga S. Expression of the hepatocyte growth factor and c-met in normal thyroid, nonneoplastic, and neoplastic nodules. Thyroid 8: 125-131, 1998. (Pubitemid 28103599)
52. Trovato M, Grosso M, Vitarelli E, Ruggeri RM, Alesci S, Trimarchi F, Barresi G, Benvenga S. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas. Histol Histopathol 18: 393-399, 2003.
53. Ghoneim C, Soula-Rothhut M, Blanchevoye C, Martiny L, Antonicelli F, Rothhut B. Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. J Biol Chem 282: 15490-15497, 2007.
54. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425, 1984.
55. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990. (Pubitemid 20149352)
56. Nicholson S, Richard J, Sainsbury C, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63: 146-150, 1991.
57. Aasland R, Akslen LA, Varhaug JE, Lillehaug JR. Co-expression of the genes encoding transforming growth factor-alpha and its receptor in papillary carcinomas of the thyroid. Int J Cancer 46: 382-387, 1990. (Pubitemid 20291089)
58. Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, Tartaglia M, Santoro M, Puxeddu E. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 25: 4235-4240, 2006.
59. Xing MZ. Genetic-Targeted Therapy of Thyroid Cancer: A Real Promise. Thyroid 19: 805-809, 2009.
60. Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, Elisei R, Santoro M, Basolo F. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 17: 381-388, 2007.
61. Liu DX, Liu Z, Condouris S, Xing MZ. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 92: 2264-2271, 2007.
62. Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology 145: 5448-5451, 2004. (Pubitemid 39564582)
63. Sapio MR, Posca D, Raggioli A, Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Troncone G, Caleo A, Rossi G, Fenzi G, Vitale M. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 66: 678-683, 2007.
64. Fusco A, Chiappetta G, Hui P, Garcia-Rostan G, Golden L, Kinder BK, Dillon DA, Giuliano A, Cirafici AM, Santoro M, Rosai J, Tallini G. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 160: 2157-2167, 2002.
65. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457, 2003.
66. Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR. Distinct Genetic Alterations in the Mitogen-Activated Protein Kinase Pathway Dictate Sensitivity of Thyroid Cancer Cells to Mitogen-Activated Protein Kinase Kinase 1/2 Inhibition. Thyroid 19: 825-835, 2009.
67. Lanzi C, Cassinelli G, Nicolini V, Zunino F. Targeting RET for thyroid cancer therapy. Biochem Pharmacol 77: 297-309, 2009.
68. Kang SW, Jeong JJ, Yun JS, Sung TY, Lee SC, Lee YS, Nam KH, Chang HS, Chung WY, Park CS. Robot-assisted endoscopic surgery for thyroid cancer: experience with the first 100 patients. Surgical Endosc 23: 2399-2406, 2009.
69. Fink M, Weinhusel A, Niederle B, Haas OA. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)". Int J Cancer 69: 312-316, 1996.
70. Cakir M, Grossman AB. Medullary Thyroid Cancer: Molecular Biology and Novel Molecular Therapies. Neuroendocrinology 90: 323-48, 2009.
71. Trovato M, Fraggetta F, Villari D, Batolo D, Mackey K, Trimarchi F, Benvenga S. Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. J Clin Endocrinol Metab 84: 3235-3240, 1999.
72. M. Trovato AU, R. Dominici. Clinico-pathological significance of cell-type-specific loss of heterozygosity on chromosome 7q21: analysis of 318 microdissected thyroid lesions. Endocr Relat Cancer 11: 365-376, 2004.
73. Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126: 700-708, 2006.
74. Cohen JB, Kalinyak JE, McDougall IR. Modern management of differentiated thyroid cancer. Cancer Biother Radiopharm 18: 689-705, 2003.
75. Stojadinovic A, Peoples GE, Libutti SK, Henry LR, Eberhardt J, Howard RS, Gur D, Elster EA, Nissan A. Development of a clinical decision model for thyroid nodules. BMC Surg 9: 12-12, 2009.
76. Favia G, Iacobone M, Zanella S, Ciarleglio FA. Management of invasive and advanced thyroid cancer. Minerva Endocrinol 34: 37-55, 2009.
77. Sipos JA. Review: Thyroid cancer: emerging role for targeted therapies Ther Adv Med Oncol 2:3-16, 2010.
78. Capdevila J, Perez-Garcia J, Obiols G, Tabernero J. Targeted therapies in thyroid cancer. Target Oncol 4: 275-285, 2009.
79. Francis Z, Baudin E, Leboulleux S, Schlumberger M. [Angiogenesis and thyroid cancer]. Presse Med 38: 1641-1646, 2009.
80. Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jurgensmeier JM, Milas L, Ang K, Herbst RS, O'Reilly MS. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 69: 1534-1543, 2007.
81. Kundra P, Burman KD. Thyroid cancer molecular signaling pathways and use of targeted therapy. Endocrinol Metab Clin North Am 36: 839-853, 2007.
82. Sugawara M, Geffner DL, Martinez D, Hershman JM. Novel treatment of medullary thyroid cancer. Curr Opin Endocrinol Diabetes Obes 16: 367-372, 2009.
83. Hoffmann S, Burchert A, Wunderlich A, Wang Y, Lingelbach S, Hofbauer LC, Rothmund M, Zielke A. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine 31: 105-113, 2007.
84. Ezra E.W. Cohen LSR, et al. Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study. JCO 26: 4708-4713, 2008.
85. Malouf G, Baudin E, Soria JC, Schlumberger M. Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies. Bulletin Du Cancer 96: 95-101, 2009.
86. Vandana Gupta-Abramson ABT. Phase II Trial of Sorafenib in Advanced Thyroid Cancer. J Clin Oncol 26: 4714-4719, 2008.
87. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE, Jr., Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27: 1675-1684, 2009.
88. Prichard CN, Kim S, Yazici YD, Doan DD, Jasser SA, Mandal M, Myers JN. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 117: 674-679, 2007.
89. Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD, Francis GL. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 12: 953-961, 2002.
90. Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, Zhang Y, White KE, Gow RM, Marshall SM, Steer BM, Marsden PA, Rakoczy PE, Gilbert RE. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A 104: 14448-14453, 2007.
91. Hoffmann S, Rockenstein A, Ramaswamy A, Celik I, Wunderlich A, Lingelbach S, Hofbauer LC, Zielke A. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol and Cell Endocrinol 264: 74-81, 2007.
92. Ulisse S, Baldini E, Toller M, Delcros JG, Gueho A, Curcio F, De Antoni E, Giacomelli L, Ambesi-Impiombato FS, Bocchini S, D'Armiento M, Arlot-Bonnemains Y. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr Relat Cancer 14: 827-837, 2007.
93. Kunnimalaiyaan M, Ndiaye M, Chen H. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 140: 1009-1014, 2006.
94. Sumitomo M, Asano T, Asakuma J, Horiguchi A, Hayakawa M. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 10: 794-801, 2004.
95. Lang BH, Lo CY. Surgical options in undifferentiated thyroid carcinoma. World J Surg 31: 969-977, 2007.